256 related articles for article (PubMed ID: 14749510)
41. 11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome.
Joharapurkar A; Dhanesha N; Shah G; Kharul R; Jain M
Pharmacol Rep; 2012; 64(5):1055-65. PubMed ID: 23238463
[TBL] [Abstract][Full Text] [Related]
42. Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11beta-HSD1 in the Syrian hamster.
Coutinho AE; Campbell JE; Fediuc S; Riddell MC
J Appl Physiol (1985); 2006 May; 100(5):1483-8. PubMed ID: 16357069
[TBL] [Abstract][Full Text] [Related]
43. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
[TBL] [Abstract][Full Text] [Related]
45. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
Loerz C; Maser E
J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.
Baudrand R; Carvajal CA; Riquelme A; Morales M; Solis N; Pizarro M; Escalona A; Boza C; Pérez G; Domínguez A; Arrese M; Fardella CE
Obes Surg; 2010 Jan; 20(1):77-83. PubMed ID: 19690925
[TBL] [Abstract][Full Text] [Related]
47. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Paterson JM; Morton NM; Fievet C; Kenyon CJ; Holmes MC; Staels B; Seckl JR; Mullins JJ
Proc Natl Acad Sci U S A; 2004 May; 101(18):7088-93. PubMed ID: 15118095
[TBL] [Abstract][Full Text] [Related]
48. Targeting 11β-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease.
Hardy RS; Seibel MJ; Cooper MS
Curr Opin Pharmacol; 2013 Jun; 13(3):440-4. PubMed ID: 23540586
[TBL] [Abstract][Full Text] [Related]
49. Cortisol--cause and cure for metabolic syndrome?
Walker BR
Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
[TBL] [Abstract][Full Text] [Related]
50. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Stulnig TM; Waldhäusl W
Diabetologia; 2004 Jan; 47(1):1-11. PubMed ID: 14652720
[TBL] [Abstract][Full Text] [Related]
51. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease.
Morton NM; Ramage L; Seckl JR
Endocrinology; 2004 Jun; 145(6):2707-12. PubMed ID: 15044372
[TBL] [Abstract][Full Text] [Related]
52. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1.
Nyirenda MJ; Carter R; Tang JI; de Vries A; Schlumbohm C; Hillier SG; Streit F; Oellerich M; Armstrong VW; Fuchs E; Seckl JR
Diabetes; 2009 Dec; 58(12):2873-9. PubMed ID: 19720800
[TBL] [Abstract][Full Text] [Related]
53. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.
Tagawa N; Minamitani E; Yamaguchi Y; Kobayashi Y
Steroids; 2011 Dec; 76(14):1546-53. PubMed ID: 21945397
[TBL] [Abstract][Full Text] [Related]
54. Transgenic overexpression of hexose-6-phosphate dehydrogenase in adipose tissue causes local glucocorticoid amplification and lipolysis in male mice.
Wang Y; Liu L; Du H; Nagaoka Y; Fan W; Lutfy K; Friedman TC; Jiang M; Liu Y
Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E543-51. PubMed ID: 24381005
[TBL] [Abstract][Full Text] [Related]
55. Benzofuran derivatives inhibit 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue.
Kiyonaga D; Tagawa N; Yamaguchi Y; Wakabayashi M; Kogure T; Ueda M; Miyata O; Kobayashi Y
Biol Pharm Bull; 2012; 35(8):1275-80. PubMed ID: 22863925
[TBL] [Abstract][Full Text] [Related]
56. A novel promoter for the 11beta-hydroxysteroid dehydrogenase type 1 gene is active in lung and is C/EBPalpha independent.
Bruley C; Lyons V; Worsley AG; Wilde MD; Darlington GD; Morton NM; Seckl JR; Chapman KE
Endocrinology; 2006 Jun; 147(6):2879-85. PubMed ID: 16543369
[TBL] [Abstract][Full Text] [Related]
57. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
Mariniello B; Ronconi V; Rilli S; Bernante P; Boscaro M; Mantero F; Giacchetti G
Eur J Endocrinol; 2006 Sep; 155(3):435-41. PubMed ID: 16914598
[TBL] [Abstract][Full Text] [Related]
58. 7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
Wamil M; Andrew R; Chapman KE; Street J; Morton NM; Seckl JR
Endocrinology; 2008 Dec; 149(12):5909-18. PubMed ID: 18755798
[TBL] [Abstract][Full Text] [Related]
59. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
[TBL] [Abstract][Full Text] [Related]
60. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
